Trending Now - Long-term Success Seen in Gene Therapy for Rare Deafness

WHO:

Nature - 42 participants aged 0.8 to 32.3 years received gene therapy.

NPR - Zheng-Yi Chen, associate scientist at Mass Eye and Ear in Boston, led the study.

NPR - Dr. Lawrence Lustig, chair of the Department of Otolaryngology-Head & Neck Surgery at Columbia University, commented on the significance of the results.

WHAT:

Nature - The study involved a single-arm, multicentre trial assessing the efficacy and safety of adeno-associated virus (AAV) serotype 1 carrying a human OTOF coding transgene (AAV1-hOTOF).

Nature - Hearing was recovered in 90% of participants treated with AAV1-hOTOF.

Nature - The auditory brainstem response threshold improved from greater than 97 ± 1 dB at baseline to 42 ± 5 dB at 2.5 years.

NPR - The study is the largest and longest to date evaluating gene therapy for hearing loss.

NPR - The treatment appears to provide a one-and-done solution that lasts a lifetime for many patients.

WHERE:

Nature - The trial was conducted at eight centres.

NPR - The study was led by researchers at Mass Eye and Ear in Boston and involved collaboration with Fudan University in China.

WHEN:

Nature - The follow-up period for the study was up to 2.5 years.

NPR - The study results were reported on April 20th, 2026.

WHY:

NPR - The research aims to provide a treatment option for genetic hearing loss, which affects about 50 babies born each year in the U.S.

HOW:

Nature - Participants received AAV1-hOTOF at three vector dose groups.

NPR - A virus called an adenovirus was used to carry a healthy version of the OTOF gene into the ears of the patients.

(UPDATED April 23, 2026 04:06 UTC)

A groundbreaking study led by Zheng-Yi Chen at Mass Eye and Ear in Boston has shown that gene therapy can significantly improve hearing in patients with genetic hearing loss, with 90% of participants recovering their hearing after treatment. The trial, which is the largest and longest of its kind, involved 42 participants and demonstrated that the auditory brainstem response threshold improved dramatically from over 97 dB to around 42 dB over a follow-up period of 2.5 years. This innovative treatment, utilizing a virus to deliver a healthy version of the OTOF gene, offers a potential lifelong solution for many patients affected by this condition.